33494-81-4

Basic information

• Product Name: DI-T-BUTYL PHOSPHORIC ACID
• Synonyms: DI-T-BUTYL PHOSPHORIC ACID;DI-TERT-BUTYL PHOSPHORIC ACID;Phosphoric acid di-tert-butyl ester;Di-tert-butyl hydrogen phosphate;Phosphoric acid,bis(1,1-dimethylethyl) ester;Phosphoric acid,bis(1,1-dimethylethyl) ester (9CI)
• CAS NO: 33494-81-4
• Molecular Formula: C₈H₁₉O₄P
• Molecular Weight: 210.21
• Mol File: 33494-81-4.mol

Chemical Properties

• Boiling Point: 252℃
• Flash Point: 106℃
• Appearance: /
• Density: 1.077
• Storage Temp.: 2-8°C
• PKA: 1.48±0.50(Predicted)
• CAS DataBase Reference: DI-T-BUTYL PHOSPHORIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: DI-T-BUTYL PHOSPHORIC ACID(33494-81-4)
• EPA Substance Registry System: DI-T-BUTYL PHOSPHORIC ACID(33494-81-4)

Safety Data

• Hazardous Substances Data: 33494-81-4(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
DI-T-BUTYL PHOSPHORIC ACID is used as a reagent for the high-yield synthetic procedure of preparing transition metal phosphate cages [M4(μ4-O)(dtbp)6] (M = Co, Zn). Its chemical properties allow it to react with metal acetates, leading to the formation of these complex structures with potential applications in various fields.
Used in Catalysts and Additives Industry:
DI-T-BUTYL PHOSPHORIC ACID can be used as a component in the development of catalysts and additives due to its ability to form stable complexes with metal ions. This property makes it suitable for enhancing the performance of catalysts in various chemical reactions and processes.
Used in Pharmaceutical and Agrochemical Industry:
The unique chemical properties of DI-T-BUTYL PHOSPHORIC ACID also make it a potential candidate for use in the pharmaceutical and agrochemical industries. It can be employed in the synthesis of complex molecules and compounds with specific biological activities, contributing to the development of new drugs and agrochemical products.
Used in Material Science:
DI-T-BUTYL PHOSPHORIC ACID's ability to form stable complexes with metal ions can also be exploited in material science for the development of new materials with specific properties. These materials could have applications in various fields, such as electronics, energy storage, and advanced coatings.

Flammability and Explosibility

Flammable

Synthetic route

potassium di-tert-butylphosphate (33494-80-3) → phosphoric acid di-tert-butyl ester (33494-81-4)

Conditions	Yield
With hydrogenchloride In water at 0℃;	98%
With hydrogenchloride In water at 0℃;
With hydrogenchloride In water Cooling with ice;

di-tert-butyl phosphite (13086-84-5) → phosphoric acid di-tert-butyl ester (33494-81-4)

Conditions	Yield
Stage #1: di-tert-butyl phosphite With potassium permanganate; potassium hydrogencarbonate In water at 0 - 60℃; for 1.75h; Stage #2: With hydrogenchloride In water at 0 - 5℃;	95%
With potassium permanganate; potassium hydrogencarbonate In water	92%
Stage #1: di-tert-butyl phosphite With potassium permanganate; sodium hydrogencarbonate In water at -5 - 25℃; for 2h; Stage #2: With hydrogenchloride In water at 0℃; pH=1 - 2;	63%

di-tert-butyl phosphite (13086-84-5) → phosphoric acid di-tert-butyl ester (33494-81-4)

Conditions	Yield
With potassium permanganate; sodium hydrogencarbonate In water	89%
With potassium permanganate; sodium hydrogencarbonate In water Cooling with ice;	89%
Stage #1: di-tert-butyl phosphite With sodium hydrogencarbonate In water at 0℃; for 0.333333h; Stage #2: With potassium permanganate at 20℃; for 1h;	89%

tert-butyl alcohol (75-65-0) → tri-(tert-butyl) phosphate (20224-50-4) + t-butyl dihydrogenphosphate (2382-75-4) + phosphoric acid di-tert-butyl ester (33494-81-4)

Conditions	Yield
With phosphorus; tetraethylammonium iodide In water; acetonitrile electrolysis;	A 80% B n/a C n/a

C4H9Sn{O2P(OC(CH3)3)2}3 → {(C4H9Sn(S)OP(OH)(OC(CH3)3)2)3S}(1+)*O2P(OC(CH3)3)2(1-)*2H2S*H2O={Sn3S4P3O12H84C36}{O4PC8H18}*2H2S*H2O + phosphoric acid di-tert-butyl ester (33494-81-4)

Conditions	Yield
With hydrogen sulfide In benzene passing H2S through a benzene soln. of tin-compd. at room temp.;

8-bromo-7-hydroxyquinoline (90224-71-8) + concentrated sodium thiosulfate + di-tert-butyl N,N-diethylphosphoramidite (117924-33-1) → phosphoric acid di-tert-butyl ester (33494-81-4)

Conditions	Yield
With 1H-tetrazole; tert.-butylhydroperoxide; triethylamine In tetrahydrofuran; water; acetonitrile

di-tert-butyl N,N-diethylphosphoramidite (117924-33-1) → phosphoric acid di-tert-butyl ester (33494-81-4)

Conditions	Yield
With 1H-tetrazole; tert.-butylhydroperoxide In tetrahydrofuran

di-tert-butyl phosphite (13086-84-5) + pyrographite (7440-44-0) → phosphoric acid di-tert-butyl ester (33494-81-4)

Conditions	Yield
With potassium hydrogencarbonate In potassium permanganate; water

di-tert-butyl phosphite (13086-84-5) → phosphoric acid di-tert-butyl ester (33494-81-4) + 1,1-dimethylethyl diphosphate

Conditions	Yield
Stage #1: di-tert-butyl phosphite With iodine In tetrahydrofuran at 20℃; Inert atmosphere; Stage #2: With pyridine; water In tetrahydrofuran at 20℃; Reagent/catalyst; Solvent; Inert atmosphere;

tert-butyl alcohol (75-65-0) → phosphoric acid di-tert-butyl ester (33494-81-4)

Conditions	Yield
With phosphorus trichloride at 40 - 50℃; for 1h;

phosphoric acid di-tert-butyl ester (33494-81-4) + tetra(n-butyl)ammonium hydroxide (2052-49-5) → di-tert-butyl phosphoric acid tetra-n-butylammonium salt (68695-48-7)

Conditions	Yield
In water; acetone Cooling with ice;	99%
In acetone at -10 - -5℃; for 0.5h;	37%
In methanol at 0℃;
In methanol

phosphoric acid di-tert-butyl ester (33494-81-4) + [Mn(OAc)(2,2′-bipyridine)2](ClO4)(H2O) → C56H68Mn2N8O8P2(2+)*2ClO4(1-)

Conditions	Yield
In methanol at 20℃; for 0.166667h;	96%

phosphoric acid di-tert-butyl ester (33494-81-4) + cobalt(II) diacetate tetrahydrate (6147-53-1) → [Co4(μ4-O)(di-tert-butyl phosphate)6]

Conditions	Yield
In tetrahydrofuran; methanol hot soln. of Co salt in MeOH added to THF soln. of ligand (molar ratio 1:1.5); stirred for ca. 12 h at room temp.; solvent removed in vac.; crystd. over 2 d on benchtop; elem. anal.;	93%

1,10-Phenanthroline (66-71-7) + phosphoric acid di-tert-butyl ester (33494-81-4) + water (7732-18-5) + copper(II) acetate monohydrate (6046-93-1) → C12H8N2[(C(CH3)3O)2PO2]2(H2O)Cu (642067-61-6)

Conditions	Yield
In methanol mixed in methanol, stirred for 5 min; evapd.(vac.), recrystd.(CH3CN/acetone 1:1), elem. anal.;	93%

phosphoric acid di-tert-butyl ester (33494-81-4) + triphenylbismuthane (603-33-8) → 2C6H5(1-)*Bi(3+)*C8H18O4P(1-)

Conditions	Yield
In ethanol at 20℃; for 24h; Reflux;	89.1%

chlorosulfuric acid chloromethyl ester (49715-04-0) + phosphoric acid di-tert-butyl ester (33494-81-4) → di-tert-butyl chloromethyl phosphate (229625-50-7)

Conditions	Yield
Stage #1: phosphoric acid di-tert-butyl ester With tetra(n-butyl)ammonium hydrogensulfate; sodium hydrogencarbonate In water for 0.166667h; Cooling with ice; Stage #2: chlorosulfuric acid chloromethyl ester In dichloromethane; water at 20℃; for 24h;	89%
With tetra(n-butyl)ammonium hydrogensulfate; sodium hydrogencarbonate In dichloromethane; water at 0 - 20℃;	72%
Stage #1: phosphoric acid di-tert-butyl ester With tetra(n-butyl)ammonium hydrogensulfate; sodium hydrogencarbonate In dichloromethane; water at 0℃; for 0.166667h; Stage #2: chlorosulfuric acid chloromethyl ester In dichloromethane; water at 20℃;	72%

2,4,6-trimethyl-pyridine (108-75-8) + phosphoric acid di-tert-butyl ester (33494-81-4) + copper(II) acetate monohydrate (6046-93-1) → Cu(di-tert-butyl phosphate)2(2,4,6-trimethylpyridine)2 (658692-36-5)

Conditions	Yield
In acetonitrile adding solid di-tert-butyl phosphate, Cu salt, and 2,4,6-trimethylpyridine to acetonitrile, heating on a water bath until solid is dissolved; filtration, crystn. over 3 d; elem. anal.;	88%

phosphoric acid di-tert-butyl ester (33494-81-4) + tetramethyl ammoniumhydroxide (75-59-2) → tetramethylammonium di-tert-butyl hydrogen phosphate (34075-24-6)

Conditions	Yield
In water; acetone at 20℃; for 0.833333h; Cooling with ice;	87%
In acetone at 0℃;	57%
In water; acetone

phosphoric acid di-tert-butyl ester (33494-81-4) + tetra(n-butyl)ammonium hydroxide (2052-49-5) → tetramethylammonium di-tert-butyl hydrogen phosphate (34075-24-6)

Conditions	Yield
In water; acetone for 0.5h;	87%

phosphoric acid di-tert-butyl ester (33494-81-4) + C23H27ClN2O9 → C31H45N2O13P

Conditions	Yield
With tetra-(n-butyl)ammonium iodide; potassium carbonate In 1,4-dioxane Inert atmosphere;	87%

1H-imidazole (288-32-4) + phosphoric acid di-tert-butyl ester (33494-81-4) + nickel(II) acetate tetrahydrate (6018-89-9) → [Ni(di-tert-butyl phosphate)2(imidazole)4] (327056-82-6)

Conditions	Yield
In tetrahydrofuran; methanol soln. of Ni salt in MeOH added to soln. of 2 equiv. of phosphate in MeOHwith stirring; 4 equiv. of imidazole in THF added slowly along the wall s; crystd. over a few d; elem. anal.;	86%

1H-imidazole (288-32-4) + phosphoric acid di-tert-butyl ester (33494-81-4) + cobalt(II) diacetate tetrahydrate (6147-53-1) → [Co(di-tert-butyl phosphate)2(imidazole)4] (327056-80-4)

Conditions	Yield
In tetrahydrofuran; methanol soln. of Co salt in MeOH added to soln. of 2 equiv. of phosphate in MeOHwith stirring; 4 equiv. of imidazole in THF added slowly along the wall s; crystd. over a few d; elem. anal.;	85%

Upstream product

• 13086-84-5 di-tert-butyl phosphite 
• 75-65-0 tert-butyl alcohol 
• 13086-84-5 di-tert-butyl phosphite 
• 7440-44-0 pyrographite 
• 117924-33-1 di-tert-butyl N,N-diethylphosphoramidite 
• 90224-71-8 8-bromo-7-hydroxyquinoline 
• 33494-80-3 potassium di-tert-butylphosphate 

Downstream Products

• 70461-25-5 Phosphoric acid di-tert-butyl ester 2-phenylsulfanyl-ethyl ester 
• 271250-91-0 (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-[[[m-di-t-butylphosphonooxymethyl]benzoyloxy]methoxy]butane 
• 229625-50-7 di-tert-butyl chloromethyl phosphate 
• 427899-56-7 bis-di-tert-butyl methyl phosphate 
• 1431216-68-0 4-(5-{2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamido}-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-{[bis(tert-butoxy)phosphoryl]oxymethyl}piperazin-1-ium 
• 1367455-49-9 [2-[2-amino-4-(isoindoline-2-carbonyl)quinazolin-6-yl]-4,5-difluorophenyl]methyl di-tert-butyl phosphate 
• 1421275-99-1 C₃₁H₃₄Br₂N₃O₈P 
• 1383139-19-2 Di-tert-butyl [2-{[(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)acetyl]imino}-4-[3-fluoro-4-(trifluoromethyl)phenyl]-1,3-thiazol-3(2H)-yl]methyl phosphate 
• 1365173-24-5 phosphoric acid di-tert-butyl ester 2-cyano-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-6-oxo-1-propyl-1,6-dihydropurin-9-ylmethyl ester 
• 1365173-21-2 phosphoric acid di-tert-butyl ester 2-cyano-6-oxo-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-1,6-dihydropurin-7-ylmethyl ester 
• 1357576-98-7 di-tert-butyl ((R)-(4'-chlorobiphenyl-2-yl)(1-(4-(4-((R)-4-morpholino-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonylcarbamoyl)-phenyl)piperidin-4-yl)methoxy)methyl phosphate 
• 1357576-21-6 (R)-4-(4-((4'-chlorobiphenyl-2-yl)(di-tert-butoxyphosphonooxymethoxy)methyl)piperidin-1-yl)benzoic acid 
• 1357577-02-6 di-tert-butyl ((R)-(4'-chlorobiphenyl-2-yl)(1-(4-(4-((R)-4-((S)-3-((diethylamino)methyl)morpholino)-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonylcarbamoyl)phenyl)piperidin-4-yl)methoxy)methyl phosphate 
• 1357575-60-0 di-tert-butyl 2-(4-((R)-3-(4-(N-(4-(4-((R)-(tert-butyldimethylsilyloxy)(4'-chlorobiphenyl-2-yl)methyl)piperidin-1-yl)benzoyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)piperazin-1-yl)ethyl phosphate 

Relevant articles and documents

A extractant composition and its preparation method and application

The invention discloses an extractant composition as well as a preparation method and an application thereof. The composition comprises the following components in percentages by weight: a component A: 80-99.99wt% of dialkyl phosphinic acid with a structure shown in a formula I; a component B: 0-5wt% of dialkyl phosphinic acid with a structure shown in a formula II; a component C: 0-5wt% of dialkyl phosphinic acid alkyl ester with a structure shown in a formula III; a component D: 0-10wt% of alkyl phosphorous acid mono alkyl ester with a structure shown in a formula IV; wherein, the component B, C and D are not zero at the same time, and the sum of the component A, B, C and D is always 100wt%. The extractant composition containing synergistic extractant components is prepared, the composition is used as an extractant and can be widely applied to rare earth metals, especially separation and purification of cobalt nickel bimetals, and compared with monocomponent extraction agents, the composition has more excellent extraction performance; compared with bis (2,4,4-trimethylpentyl)-phosphinic acid, other synergistic extractant components are easy to synthesize, and production cost of the product is reduced.

GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.

Novel triclabendazole prodrug: A highly water soluble alternative for the treatment of fasciolosis

In this work we present the synthesis, aqueous solubility and stability, hydrolysis by alkaline phosphatase, and in vivo fasciolicidal activity in sheep of a highly water soluble phosphate salt prodrug of triclabendazole (MFR-5). The aqueous solubility of MFR-5 at pH 7 was 88,000-fold that of triclabendazole. MFR-5 showed excellent aqueous stability (>95% after 26?h) at pH 7, making it ideal for developing pharmaceutical compositions in the form of solutions that can easily be hydrolyzed by the enzyme alkaline phosphatase (t?=?13.6?s) to liberate the precursor compound. An aqueous solution of MFR-5 administered intramuscularly to sheep at concentrations of 4, 6 and 8?mg/kg presented a fasciolicidal efficiency of 96.5%, 98.4% and 99.2%, respectively. In the in vivo experiments, MFR-5 reduced 100% the excretion of eggs in all of the above concentrations.

NOVEL HYDROSOLUBLE COMPOUNDS DERIVED FROM BENZIMIDAZOLE USED IN TREATING FASCIOLOSIS

The present invention relates to hydrosoluble compounds derived from benzimidazole represented by general formula I: wherein: Y1 e Y2 are independently O or S, and at least one of Y1 and Y2 is O; R1 and R2 are independently hydrogen or a cation, both are hydrogen or both are cations; R3 is a C1-4 alkyl; R4 and R5 are independently halogen or a —OR6 alkoxide; R6 is C6-C10 aryl linked in 5- or 6-position of benzimidazole nucleus.

METHODS OF BLADDER CANCER TREATMENT WITH CICLOPIROX, CICLOPIROX OLAMINE, OR A CICLOPIROX PRODRUG

A method of treating bladder cancer is provided. The method of treating bladder cancer can include: providing a pharmaceutical composition having ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug having a structure of one of the formulae provided herein or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the pharmaceutical composition to a subject having the bladder cancer. The ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug can be administered in a therapeutically effective amount.

4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator

Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof.

METHOD OF TREATMENT WITH PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDIN IN-2-1H-ONE AND DERIVATIVES THEREOF

A prodrug can have a structure of Formula 10 or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, cancer, dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis, candidiasis (moniliasis), Candida albicans, tinea (pityriasis) vesicolor, Malassezia furfur, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma.

Development of efficient processes for the preparation of Di-tert-butyl potassium phosphate and Di-tert-butyl (Chloromethyl) phosphate

A new and efficient process to prepare di-tert-butyl (chloromethyl) phosphate, a key compound in the formation of many phosphon-oxymethyl pro-drugs, from chloromethyl chlorosulfate (CMCS) and di-tert-butyl potassium phosphate (DTBPP) is described. To develop a process to this important compound with overall efficiency, an improved synthesis of DTBPP was required. The two-step process to DTBPP starts from PCl3 and leverages a H2O 2/catalytic KI mediated oxidation of di-tert-butyl phosphite to provide DTBPP in 81% yield and high purity. In the development of the new process to di-tert-butyl (chloromethyl) phosphate, a comparison to the corresponding tosylate derivative was made. A rational selection of base, phase-transfer catalyst (PTC), and stabilizing additive minimized CMCS decomposition and led to an optimized yield (90% solution yield), improved product purity, and identification of a technique to enable the long-term storage of di-tert-butyl (chloromethyl) phosphate.

A highly water soluble benzimidazole derivative useful for the treatment of fasciolosis

This study describes the synthesis of compound (7), a highly hydrosoluble phosphonooxymethyl prodrug of compound alpha (4). Compound (7) improved the aqueous solubility of its precursor compound (4) by 50,000 times and it is stable at neutral pH. The prodrug showed faciolicidal activity when evaluated in vitro against excysted Fasciola hepatica metacercariae. The in vivo evaluation of (7) was carried out via oral, intramuscular and subcutaneous administration in sheep artificially infected with F. hepatica metacercariae. At an intramuscular dose of 4 mg/kg, the activity of (7) was similar to that of compound alpha (4) at an oral dose of 15 mg/kg.

PHOSPHATE PRODRUGS

Phosphate and phosphonate prodrug derivatives, for example of Formula IV; where p, A, LA, and R1, R3-R6 are as defined herein, are useful for treating various disorders, including diarrhea.